422 related articles for article (PubMed ID: 25737124)
1. Production of Biopharmaceuticals in E. coli: Current Scenario and Future Perspectives.
Baeshen MN; Al-Hejin AM; Bora RS; Ahmed MM; Ramadan HA; Saini KS; Baeshen NA; Redwan EM
J Microbiol Biotechnol; 2015 Jul; 25(7):953-62. PubMed ID: 25737124
[TBL] [Abstract][Full Text] [Related]
2. Current trends in biopharmaceuticals production in Escherichia coli.
McElwain L; Phair K; Kealey C; Brady D
Biotechnol Lett; 2022 Aug; 44(8):917-931. PubMed ID: 35796852
[TBL] [Abstract][Full Text] [Related]
3. Advanced technologies for improved expression of recombinant proteins in bacteria: perspectives and applications.
Gupta SK; Shukla P
Crit Rev Biotechnol; 2016 Dec; 36(6):1089-1098. PubMed ID: 26384140
[TBL] [Abstract][Full Text] [Related]
4. Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements.
Huang CJ; Lin H; Yang X
J Ind Microbiol Biotechnol; 2012 Mar; 39(3):383-99. PubMed ID: 22252444
[TBL] [Abstract][Full Text] [Related]
5. Systems metabolic engineering of Escherichia coli for the heterologous production of high value molecules-a veteran at new shores.
Becker J; Wittmann C
Curr Opin Biotechnol; 2016 Dec; 42():178-188. PubMed ID: 27513555
[TBL] [Abstract][Full Text] [Related]
6. Production of functional inclusion bodies in endotoxin-free Escherichia coli.
Rueda F; Cano-Garrido O; Mamat U; Wilke K; Seras-Franzoso J; García-Fruitós E; Villaverde A
Appl Microbiol Biotechnol; 2014 Nov; 98(22):9229-38. PubMed ID: 25129611
[TBL] [Abstract][Full Text] [Related]
7. Revisiting Escherichia coli as microbial factory for enhanced production of human serum albumin.
Sharma A; Chaudhuri TK
Microb Cell Fact; 2017 Oct; 16(1):173. PubMed ID: 28982367
[TBL] [Abstract][Full Text] [Related]
8. Automated disposable small scale reactor for high throughput bioprocess development: a proof of concept study.
Bareither R; Bargh N; Oakeshott R; Watts K; Pollard D
Biotechnol Bioeng; 2013 Dec; 110(12):3126-38. PubMed ID: 23775295
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the metabolic engineering of microorganisms for the production of 3-hydroxypropionic acid as C3 platform chemical.
Valdehuesa KN; Liu H; Nisola GM; Chung WJ; Lee SH; Park SJ
Appl Microbiol Biotechnol; 2013 Apr; 97(8):3309-21. PubMed ID: 23494623
[TBL] [Abstract][Full Text] [Related]
10. Recent progress in therapeutic natural product biosynthesis using Escherichia coli.
Ahmadi MK; Pfeifer BA
Curr Opin Biotechnol; 2016 Dec; 42():7-12. PubMed ID: 26942861
[TBL] [Abstract][Full Text] [Related]
11. Optimizing scaleup yield for protein production: Computationally Optimized DNA Assembly (CODA) and Translation Engineering.
Hatfield GW; Roth DA
Biotechnol Annu Rev; 2007; 13():27-42. PubMed ID: 17875472
[TBL] [Abstract][Full Text] [Related]
12. Strategies for the production of difficult-to-express full-length eukaryotic proteins using microbial cell factories: production of human alpha-galactosidase A.
Unzueta U; Vázquez F; Accardi G; Mendoza R; Toledo-Rubio V; Giuliani M; Sannino F; Parrilli E; Abasolo I; Schwartz S; Tutino ML; Villaverde A; Corchero JL; Ferrer-Miralles N
Appl Microbiol Biotechnol; 2015 Jul; 99(14):5863-74. PubMed ID: 25616525
[TBL] [Abstract][Full Text] [Related]
13. Advances in engineered microorganisms for improving metabolic conversion via microgravity effects.
Huangfu J; Zhang G; Li J; Li C
Bioengineered; 2015; 6(4):251-5. PubMed ID: 26038088
[TBL] [Abstract][Full Text] [Related]
14. Examining the feasibility of bulk commodity production in Escherichia coli.
Vickers CE; Klein-Marcuschamer D; Krömer JO
Biotechnol Lett; 2012 Apr; 34(4):585-96. PubMed ID: 22160295
[TBL] [Abstract][Full Text] [Related]
15. Genetic engineering modification and fermentation optimization for extracellular production of recombinant proteins using Escherichia coli.
Zhou Y; Lu Z; Wang X; Selvaraj JN; Zhang G
Appl Microbiol Biotechnol; 2018 Feb; 102(4):1545-1556. PubMed ID: 29270732
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of medium chain length fatty acid ethyl esters in engineered Escherichia coli using endogenously produced medium chain fatty acids.
Fan L; Liu J; Nie K; Liu L; Wang F; Tan T; Deng L
Enzyme Microb Technol; 2013 Jul; 53(2):128-33. PubMed ID: 23769314
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial pathway engineering for optimized production of the anti-malarial FR900098.
Freestone TS; Zhao H
Biotechnol Bioeng; 2016 Feb; 113(2):384-92. PubMed ID: 26245694
[TBL] [Abstract][Full Text] [Related]
18. Vaccine process technology.
Josefsberg JO; Buckland B
Biotechnol Bioeng; 2012 Jun; 109(6):1443-60. PubMed ID: 22407777
[TBL] [Abstract][Full Text] [Related]
19. Cellular targets for improved manufacturing of virus-based biopharmaceuticals in animal cells.
Rodrigues AF; Carrondo MJ; Alves PM; Coroadinha AS
Trends Biotechnol; 2014 Dec; 32(12):602-7. PubMed ID: 25450042
[TBL] [Abstract][Full Text] [Related]
20. Escherichia coli for biofuel production: bridging the gap from promise to practice.
Huffer S; Roche CM; Blanch HW; Clark DS
Trends Biotechnol; 2012 Oct; 30(10):538-45. PubMed ID: 22921756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
